Agoracom Blog Home

Archive for the ‘Novamind Inc.’ Category

@Novamind_Inc $NM.ca $NVMDF Weekly Roundup $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 11:06 AM on Saturday, March 6th, 2021

A weekly summary of Novamind news and media

FEATURES March 2, 2021

Dr. Reid Robison on Novamind’s Innovative Approach to Psychedelic Medicine

Novamind’s Chief Medical Officer discusses the growing need for breakthrough mental health treatments and how Novamind is helping to bring psychedelic medicine into everyday healthcare.

View all media

Novamind Expands Leadership Team, Accelerating M&A

March 3, 2021

Novamind Reports Company Highlights and Strong Revenue Growth in Fiscal Second Quarter

March 1, 2021

View all press releases

Follow @novamind_inc on Instagram

Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly-owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca

Novamind $NM.ca $NVMDF Expands Leadership Team, Accelerating M&A $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 8:52 AM on Wednesday, March 3rd, 2021
  • Announced the appointment of Joseph Braganza to the role of Senior Vice President, Head of M&A.
  • Mr. Braganza joins the senior leadership team with a mandate to lead Novamind’s M&A strategy, accelerating the Company’s expansion plans for its network of clinics, retreats and clinical research sites.

TORONTO, ON / March 3, 2021 / Novamind Inc.,(CSE:NM)(OTC PINK:NVMDF) (“Novamind” or the “Company”), a leading mental health company specialized in psychedelic medicine, announces the appointment of Joseph Braganza to the role of Senior Vice President, Head of M&A. Mr. Braganza joins the senior leadership team with a mandate to lead Novamind’s M&A strategy, accelerating the Company’s expansion plans for its network of clinics, retreats and clinical research sites.

Joseph has gained tenure as a M&A specialist and strategist, building sustainable programmatic M&A approaches for high-growth organizations. Leveraging over 20 years of professional experience, Joseph recently led the M&A group as Vice President, Business and Corporate Development at Canadian Addiction Treatment Centres (CATC), a consolidator of outpatient addiction treatment clinics that currently operates over 70 clinics and an inpatient residential treatment facility. Joseph previously held senior M&A roles at People Corp. (acquired by Goldman Sachs Merchant Banking), Rexall Health Solutions (a subsidiary of McKesson Corp.) and Deloitte.

“I am deeply committed to Novamind’s vision to scale their operating model for psychedelic medicine,” Braganza commented. “Facilitating greater access to these breakthrough treatments is critical in helping people find new ways to improve their mental health. I look forward to working with the leadership team as we pursue Novamind’s vision.”

Yaron Conforti, CEO and Director of Novamind added, “We’re excited to announce Joseph’s appointment to lead our M&A team. Joseph’s experience acquiring and integrating businesses, combined with his expertise in the mental health sector make him uniquely positioned to contribute to Novamind’s strategic growth plans.”

Read More: https://agoracom.com/ir/Novamind/forums/discussion/topics/756466-novamind-expands-leadership-team-accelerating-m-a/messages/2306202#message

@Novamind_Inc $NM.ca $NVMDF Reports Company Highlights and Strong Revenue Growth in Fiscal Second Quarter $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 8:29 AM on Monday, March 1st, 2021
  • $1.29 million in fiscal second quarter revenue
  • Clinics see continued surge in demand for mental health services
  • Ongoing expansion of clinic capacity

TORONTO, ON / March 1, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF) (“Novamind” or “the Company”), a leading mental health company specialized in psychedelic medicine, today reported its fiscal second quarter results for the three months ended December 31, 2020 (“Fiscal Q2 2021″). The Company’s fiscal year-end is June 30th. All results are reported under International Financial Reporting Standards (“IFRS”) and in Canadian dollars, unless otherwise specified.

Fiscal Q2 2021 Highlights and Subsequent Developments

Financing and Public Listing

Novamind successfully closed an oversubscribed $10,000,000 financing on November 23rd, 2020. The funds were made available to the Company upon the completion of its reverse takeover (“RTO”) transaction and conditional listing approval from the Canadian Securities Exchange (“CSE”). The company ended the quarter with a cash balance of $10,868,742. With its strong cash position, Novamind is well-positioned to execute on its growth strategy to expand its network of mental health clinics, retreats and clinical research sites.

On January 5th, 2021, Novamind began trading on the CSE under the stock symbol “NM”. Less than two months after going public on the CSE, Novamind achieved the milestone of being included in the underlying index of the Horizons Psychedelic Stock Index ETF (NEO: PSYK) through a “Fast Entry” category, further increasing its profile with retail and institutional investors in the psychedelic medicine sector.

The Company announced on February 19th, 2021, that its common shares commenced trading under the symbol “NVMDF” on the OTC Market. In the near future, Novamind intends to apply to list its common shares on the OTCQB Market, an established marketplace in the United States for promising, innovative companies.

Operational Highlights

On January 28th, 2021, Novamind announced that it had reached two significant milestones at its Cedar Psychiatry mental health clinics: administering over 5,000 ketamine treatments since its opening in 2016, and administering over 2,000 Spravato™ treatments since the product became available in 2019. These milestones position Novamind as one of North America’s top providers of ketamine-assisted psychotherapy and Spravato™.

On January 13th, 2021, the Company announced the expansion and optimization of its Layton, Utah clinic. The redesigned Layton Clinic now offers improved treatment rooms to accommodate a higher number of ketamine and Spravato™ treatments. The Layton Clinic expansion comes in response to a significant increase in demand for ketamine therapies across Novamind’s mental health clinics. In 2020 alone, the Cedar Psychiatry clinic network facilitated over 20,000 client visits, an increase of over 100 percent compared to the same period in 2019.

On January 19th, 2021, Novamind announced the expansion of its leadership team with the appointment of Pierre Bou-Mansour, P.Eng., to the role of Chief Operating Officer. Mr. Bou-Mansour assumes the responsibility for ensuring operational excellence as Novamind develops its network of clinics, retreats, and research sites. An accomplished senior executive and leader, he brings a wealth of experience managing large and complex healthcare organizations. Prior to joining Novamind, Pierre served as the Chief Operating Officer of LifeLabs, a diagnostic laboratory services company he helped to scale into an industry leader with 5,700 employees and 370 patient access sites in Canada. Most recently, he served as the Chief Laboratory Operations Officer of Public Health Ontario, serving Canada’s largest province with over 14 million residents. In this role, Bou-Mansour successfully led the expansion of Public Health Ontario’s testing capacity for the COVID-19 response.

Strategic Investment in Bionomics

On February 11th, 2021, the Company announced that it had made a strategic investment of AU$827,486 (approximately CAN$810,000), in Bionomics Limited (“Bionomics”) (ASX: BNO, OTCQB: BNOEF, Germany: AU000000BNO5), a biopharmaceutical company dedicated to developing better treatments for central nervous system disorders. In addition, Cedar Clinical Research, a wholly owned subsidiary of Novamind, will be evaluated by Bionomics as a clinical research site to conduct Bionomics’ phase IIb clinical trial examining BNC210, a drug that has received Fast Track Designation from the U.S. Food and Drug Administration for the treatment of post-traumatic stress disorder (PTSD).

Impact of COVID-19

Novamind has not been significantly affected by the COVID-19 pandemic. As reported across multiple media outlets, the COVID-19 pandemic has resulted in a significant increase in the incidence of mental health problems, in particular anxiety and depression, conditions that are commonly treated by Novamind. The Company’s Cedar Psychiatry network of clinics continues to experience steady demand for mental health services, and this demand is anticipated to continue despite COVID-related restrictions.

Financial Highlights and Selected Consolidated Financial Information

In Fiscal Q2 2021, Novamind reported revenue of $1,288,828 primarily composed of patient services revenue from its network of four Cedar Psychiatry outpatient mental health clinics in Utah. This represents a 47 percent increase over the previous quarter ended September 30th, 2020.

The Company reported a net loss of $3,567,883 for the three months ended December 31st, 2020, as compared to a net loss of $493,614 for the prior quarter ended September 30th, 2020. The net loss for the second fiscal quarter was primarily due to expenses related to the Company’s listing on the CSE, and funding of capacity expansion at its Cedar Psychiatry clinics. This includes consulting expenses of $416,268, professional fees of $450,419, salaries and wages of $791,078, office and general expenses of $87,368, advertising and promotion expenses of $236,650, and stock-based compensation of $664,814. Additionally, there was $1,379,144 in RTO transaction costs in the quarter.

The following table presents selected financial information from the Company’s unaudited condensed interim financial statements for the three and six months ended December 31st, 2020, and periods ended December 31st, 2019.

The following information should be read in conjunction with the financial statements and management’s discussion and analysis, which are available under the Company’s SEDAR profile at www.sedar.com.

About Novamind

Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.

Contact Information

Novamind
Yaron Conforti, CEO and Director

Telephone: +1 (647) 953 9512
Bill Mitoulas, Investor Relations
Email: [email protected]

Forward-Looking Statements

This news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations including the risks detailed from time to time in the Company’s public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.

SOURCE: Novamind Inc.

@Novamind_Inc $NM.ca $NVMDF Weekly Roundup $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 11:32 AM on Saturday, February 27th, 2021

A weekly summary of Novamind news and media

FEATURES February 24, 2021

Expanding Access and Feeding Demand for New Treatment Options

Yaron Conforti spoke to CSE TV about how Novamind is creating access points to alternative mental health treatments.

View all media

Novamind to Present at Benzinga Conference

February 23, 2021

Novamind Fast Tracked for Inclusion in Horizons Psychedelic ETF

February 22, 2021

View all press releases

Follow @novamind_inc on Instagram

Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly-owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit www.novamind.ca

Novamind $NM.ca $NVMDF to Present at Benzinga Conference $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 12:08 PM on Tuesday, February 23rd, 2021
  • Announced its participation in the Benzinga Cannabis Capital Conference, on February 25th and 26th, 2021, one of the select companies to be featured from the emerging psychedelics industry.
  • On Friday, February 26th, 2021 at 1:30pm EST, Novamind’s CEO and Director, Yaron Conforti, will present the Company’s vision for scaling access to psychedelic medicine and advancing clinical research.

TORONTO, ON / February 23, 2021 / Novamind Inc. (CSE:NM) (OTC PINK:NVMDF) (“Novamind” or “the Company”), a leading mental health company specialized in psychedelic medicine, is pleased to announce its participation in the Benzinga Cannabis Capital Conference (“the Conference”), on February 25th and 26th, 2021, one of the select companies to be featured from the emerging psychedelics industry.

On Friday, February 26th, 2021 at 1:30pm EST, Novamind’s CEO and Director, Yaron Conforti, will present the Company’s vision for scaling access to psychedelic medicine and advancing clinical research.

“We are excited to connect with investors who share our belief that innovative mental health therapies are disrupting the current standard of care in mental health,” said Yaron Conforti, CEO and Director of Novamind. “I look forward to this opportunity to share Novamind’s approach to mental healthcare and clinical research in psychedelic medicine.”

The Conference will also host a panel discussion on psychedelics with industry leaders including Novamind’s Chief Medical Officer, Dr. Reid Robison on Friday, February 26th, 2021 at 1:50pm EST.

For more information about the conference, please click here.

About Novamind
Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.

Contact Information:

Novamind
Yaron Conforti, CEO and Director
Telephone: +1 (647) 953 9512

Bill Mitoulas, Investor Relations
Email: [email protected]

Forward-Looking Statements
This news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations including the risks detailed from time to time in the Company’s public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.

SOURCE: Novamind Inc.

@Novamind_Inc $NM.ca $NVMDF Weekly Roundup $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 9:54 AM on Saturday, February 20th, 2021

A weekly summary of Novamind news and media

FEATURES February 19, 2021

Dr. Reid Robison on Our Purpose-Driven Mission to Help People who are Suffering

Agoracom interviewed our Chief Medical Officer about our latest expansions, the striking results from treatments, and what it takes to build infrastructure for psychedelic-assisted healthcare.

FEATURES February 18, 2021

Novamind Leading the Charge to Deliver Mental Health Alternatives

Psychedelic Invest published an article about the urgent need for innovative mental health treatments, and the companies working to meet that need.

View all media

Novamind Announces Symbol Change on OTC Market To “NVMDF”

February 19, 2021

View all press releases

Follow @novamind_inc on Instagram

Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly-owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit www.novamind.ca

@Novamind_Inc $NM.ca Announces Symbol Change on OTC Market To $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 9:13 AM on Friday, February 19th, 2021
  • To commence trading on the OTC Pink Market under the symbol “NVMDF” effective February 19, 2021.
  • The Company’s common shares will continue to trade on the Canadian Securities Exchange under the symbol “NM”.

TORONTO, ON / ACCESSWIRE / February 19, 2021 / Novamind Inc., (CSE:NM)(OTC PINK:NVMDF) (“Novamind” or the “Company”) a mental health company specialized in psychedelic medicine, announces that its common shares, previously listed for trading on the OTC Pink Market in the United States under the symbol “HNLMF”, are to commence trading on the OTC Pink Market under the symbol “NVMDF” effective February 19, 2021. The Company’s common shares will continue to trade on the Canadian Securities Exchange under the symbol “NM”.

Novamind intends to apply to list its common shares on the OTCQB Market in the near future. The OTCQB Market is an established financial market in the United States for promising, investor-focused companies based in America or internationally.

About Novamind

Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly-owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit www.novamind.ca.

Read more: https://agoracom.com/ir/Novamind/forums/discussion/topics/755663-novamind-announces-symbol-change-on-otc-market-to-nvmdf/messages/2304371#message

VIDEO – Novamind $NM.ca Is Building the Infrastructure Required for a Regulated Psychedelics Industry $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 4:11 PM on Wednesday, February 17th, 2021

The global behavioural health market size is expected to reach approximately US$ 245 billion by 2027 and estimated to grow at CAGR of 2.5 % over the forecast time frame 2020 to 2027. 

As a consequence of the increasing incidence of mental health disorders, global demand for mental health facilities is increasing.

Psychedelics are going to go through parabolic, paradigm-shifting growth because of their ability to treat anxiety and depression amongst other things

Novamind is a leading mental health company specialized in psychedelic medicine, building the infrastructure required for a regulated psychedelics industry.

Highlights:

  • Rapidly expanding a network of outpatient mental health clinics and research sites
  • 4 clinics in Utah, 1 more anticipated this quarter
  • Provides ketamine-assisted psychotherapy and Spravato™ (esketamine) treatments;
    • Ketamine treatment volume grew 90% from 2019 to 2020
    • During the same period, total Spravato™ treatments rose 400%
  • Positioned to facilitate MDMA and psilocybin therapy post-FDA approval
  • Building centers of excellence for future approved psychedelic treatments
  • Approximately CAN$1,900,000 in 2019 revenue
  • Strong insider ownership (32.3%)

Watch this powerful interview with Dr. Reid Robison, Chief Medical Officer and Director of Novamind.

@Novamind_Inc $NM.ca Weekly Roundup $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 11:39 AM on Saturday, February 13th, 2021

A weekly summary of Novamind news and media

FEATURES February 7, 2021

Novamind’s Dr. Reid Robison on Building a Network for Psychedelic Medicine

With years of experience studying and administering ketamine, Dr. Robison discusses psychedelic infrastructure and the change it can create

FEATURES February 7, 2021

Therapy with Substance

There are millions of people who have been diagnosed with a mental health issue that are resistant to the current range of available treatments.

View all media

Novamind Announces Strategic Investment in Bionomics to Support PTSD Clinical Trial

February 11, 2021

View all press releases

Follow @novamind_inc on Instagram

Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly-owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit www.novamind.ca

CLIENT FEATURE: Novamind $NM.ca Leaders In #Psychedelic Medicine $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 11:44 AM on Friday, February 12th, 2021

NM: CSE

Why Novamind?

  • Building the infrastructure required for a regulated psychedelics industry
  • Rapidly expanding a network of outpatient mental health clinics and research sites
  • Provides ketamine-assisted psychotherapy and Spravato™ (esketamine) treatments;
    • Ketamine treatment volume grew 90% from 2019 to 2020
    • During the same period, total Spravato™ treatments rose 400%
  • Positioned to facilitate MDMA and psilocybin therapy post-FDA approval
  • Specializing in psychedelic-assisted treatment protocols
  • Building centers of excellence for future approved psychedelic treatments
  • Approximately CAN$1,900,000 in 2019 revenue
  • Strong insider ownership (32.3%) 

Yaron Conforti, CEO of Novamind Featured On Cheddar News

Novamind is focused on 3 pillars:

FULL DISCLOSURE: Novamind is an advertising client of AGORA Internet Relations Corp.

Hub On AGORACOM / Corporate Profile